NDASUBCUTANEOUSPOWDER
Approved
Dec 2008
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FIRMAGON (degarelix) is a small-molecule GnRH antagonist subcutaneous injection approved in 2008 for advanced prostate cancer. It works by rapidly suppressing luteinizing hormone and testosterone levels, offering an alternative to GnRH agonists. The powder formulation requires reconstitution before administration.
$0.001BPart D
PeakStable
5.6 years to LOEProduct is at peak commercial maturity with modest Part D claims (1,842 in 2023), suggesting a stable but niche market position with limited team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer
Started Jul 2024
208 enrolled
Prostate Cancer
Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer
Started Feb 2020
26 enrolled
Prostate Cancer
FIRMAGON® Intensive Drug Monitoring
Started Aug 2019
1,454 enrolled
Prostate Cancer
Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix
Started Jun 2017
150 enrolled
Prostate Cancer
Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix
Started Jun 2017
35 enrolled
Prostate Cancer
Worked on FIRMAGON at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.